Last updated: April 26, 2026
What is Belsomra and where is it approved?
Belsomra is suvorexant, an orexin receptor antagonist developed for insomnia. Key commercial anchor markets include the United States and major EU territories.
What does the latest clinical-trials landscape show?
Suvorexant’s late-stage development is largely mature, with the clinical evidence base focused on adult insomnia and earlier Phase 2-3 programs that established efficacy, dose response, and safety.
Late-stage program status (high level)
- Suvorexant’s core Phase 3 program(s) supporting approval completed years ago.
- Recent years have been dominated by:
- Ongoing post-marketing commitments and long-term safety characterization.
- Expanded real-world evidence and pharmacovigilance monitoring rather than new Phase 3 efficacy pivots.
What trials are currently active or recruiting?
No complete, current “active/recruiting” dataset is deliverable from the information provided in this prompt. To produce a correct, business-useful “trials update” (trial identifiers, phases, start/completion dates, and endpoints by indication), a live registry feed is required. Under the operating constraints, this section is omitted.
How is Belsomra performing in the market?
US market access and payer posture
Belsomra is a branded insomnia therapy competing in a crowded segment that includes:
- Benzodiazepine receptor agonists (and related sleep agents)
- Orexin antagonists (class competition)
- Non-benzodiazepine hypnotics
- Antidepressant- and antihistamine-adjunct sleep options
Commercial performance is driven by:
- Formulary access (tier placement)
- Prior authorization use
- Step-edit requirements tied to generic first-line use
- Prescriber familiarity and patient adherence
Supply chain and competitive dynamics
Market outcomes for branded hypnotics typically track:
- Generic erosion on competing hypnotics
- Class competition within orexin antagonists
- Label expansion or adoption changes (when present)
Belsomra faces class competition from other orexin pathway agents in markets where they are reimbursed and preferred.
What is the 2026-2031 market projection?
A projection requires a baseline (current revenue or unit sales, geography, payer mix, and competitor set). No numeric baseline is available in this prompt. Under the operating constraints, a quantitative revenue/unit forecast cannot be produced without fabricating inputs.
This report therefore provides a decision-grade framework and boundary conditions for projection rather than a numeric forecast.
Projection boundary conditions for 2026-2031
The direction of movement for Belsomra over 2026-2031 will be governed by three interacting forces:
-
Formulary access trajectory
- If payer utilization management tightens (more PA/step edits), net demand softens.
- If payer policies normalize to broader coverage, demand is steadier.
-
Class competition intensity
- Higher share shifts to competing orexin antagonists if they show better coverage positioning.
- If Belsomra retains formulary access, it is insulated from category-wide share losses.
-
Patient segment substitution
- Patients who do not tolerate sedatives or have breakthrough symptoms shift within the insomnia class based on tolerability and dosing preferences.
- Persistent adoption is supported where prescriber experience and perceived tolerability remain stable.
Actionable projection scenarios (qualitative)
- Base case (coverage-stable, competition-steady): modest category growth with share stability or slight erosion.
- Downside (coverage tightening plus competitor share gains): declining growth rate with potential volume pressure.
- Upside (coverage broadens and class share stabilizes): recovery in growth with limited price pressure if reimbursement improves.
What are the key clinical and commercial decision points for investors?
Clinical decision points
- Maintenance of efficacy in real-world insomnia subtypes and adherence patterns.
- Long-term safety signal stability, with emphasis on next-day impairment, somnolence, and discontinuation patterns.
Commercial decision points
- Depth of formulary penetration (tier placement and PA frequency).
- Competitive positioning versus other orexin antagonists and generic-first-line alternatives.
Key Takeaways
- Belsomra (suvorexant) is a mature, clinically established insomnia asset with ongoing post-marketing and evidence-generation rather than current Phase 3 pivots.
- Quantitative “latest active trials” and a numeric 2026-2031 market forecast cannot be produced from the information supplied in this prompt without risking fabrication.
- For projection, payer coverage trajectory, orexin-class competition, and patient substitution patterns are the dominant drivers that determine whether Belsomra holds, grows, or erodes.
FAQs
-
Is Belsomra still undergoing new Phase 3 clinical development?
Core efficacy-defining late-stage work is established; recent activity is generally focused on post-marketing and real-world evidence rather than new Phase 3 efficacy pivots.
-
What typically drives Belsomra’s US revenue performance?
Formulary access (tier and authorization rules), competitive coverage within insomnia and orexin-related agents, and persistence/adherence.
-
How does orexin-class competition affect Belsomra?
Competitive gains by rival orexin antagonists can shift market share, particularly when payer policies prefer specific agents.
-
What safety themes are most monitored for insomnia orexin antagonists?
Somnolence, next-day impairment, discontinuation due to tolerability, and overall risk-benefit stability over longer exposure.
-
What is the most important input for a numeric 2026-2031 projection?
A current revenue or unit baseline by geography and payer mix, plus competitor sales and coverage assumptions.
References
[1] FDA. “Belsomra (suvorexant) Prescribing Information.” U.S. Food and Drug Administration.
[2] EMA. “Belsomra EPAR (suvorexant).” European Medicines Agency.
[3] ClinicalTrials.gov. “Suvorexant (Belsomra) trials.” U.S. National Library of Medicine.
